Biogen Inc. (NASDAQ:BIIB) Given Average Rating of “Hold” by Brokerages

Shares of Biogen Inc. (NASDAQ:BIIB) have earned an average recommendation of “Hold” from the twenty-seven brokerages that are covering the stock, MarketBeat Ratings reports. Fifteen research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $205.0385.

BIIB has been the topic of a number of research reports. Royal Bank Of Canada raised their price target on Biogen from $217.00 to $233.00 and gave the stock an “outperform” rating in a research note on Monday, February 9th. Citigroup boosted their price objective on Biogen from $185.00 to $215.00 and gave the company a “neutral” rating in a research note on Monday, February 9th. Wedbush raised their target price on shares of Biogen from $178.00 to $187.00 and gave the stock a “neutral” rating in a research report on Monday, February 9th. Robert W. Baird cut their target price on shares of Biogen from $255.00 to $250.00 in a report on Friday, October 31st. Finally, Piper Sandler upped their price target on shares of Biogen from $157.00 to $177.00 and gave the company a “neutral” rating in a research report on Monday, February 9th.

Insider Transactions at Biogen

In other Biogen news, insider Priya Singhal sold 2,660 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the sale, the insider directly owned 8,043 shares of the company’s stock, valued at $1,607,232.69. This represents a 24.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.18% of the stock is owned by company insiders.

Institutional Investors Weigh In On Biogen

Several large investors have recently modified their holdings of the stock. WPG Advisers LLC increased its stake in Biogen by 417.9% in the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 117 shares during the period. First Horizon Corp purchased a new stake in shares of Biogen in the fourth quarter valued at about $30,000. Root Financial Partners LLC increased its stake in shares of Biogen by 198.4% during the fourth quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 123 shares during the period. MV Capital Management Inc. purchased a new position in Biogen during the fourth quarter worth about $34,000. Finally, GoalVest Advisory LLC acquired a new stake in Biogen in the fourth quarter valued at about $35,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen Trading Down 1.4%

Shares of Biogen stock opened at $188.02 on Friday. The company has a current ratio of 2.68, a quick ratio of 2.03 and a debt-to-equity ratio of 0.34. The company has a fifty day simple moving average of $181.64 and a 200-day simple moving average of $162.83. The stock has a market cap of $27.59 billion, a price-to-earnings ratio of 21.34, a PEG ratio of 1.51 and a beta of 0.16. Biogen has a 12-month low of $110.04 and a 12-month high of $202.41.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. The firm had revenue of $2.28 billion during the quarter, compared to analysts’ expectations of $2.21 billion. Biogen had a net margin of 13.07% and a return on equity of 12.64%. Biogen’s quarterly revenue was down 7.2% compared to the same quarter last year. During the same period in the previous year, the company earned $3.44 earnings per share. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, equities analysts forecast that Biogen will post 15.83 EPS for the current fiscal year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.